The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.
Studies designed, executed, and funded by an Alkermes company.
Showing 10 of 103 results
Sort by date:
Descending
Jul 2018
Effect of aripiprazole lauroxil in patients with acute schizophrenia as assessed by the positive and negative syndrome scale - supportive analyses from a phase 3 study
CNS Spectrums
AUTHOR(S)
May 2018
Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial
Drug and Alcohol Dependence
AUTHOR(S)
Apr 2018
A randomized, double-blind, placebo-controlled proof of concept study to evaluate samidorphan in the prevention of olanzapine-induced weight gain in healthy volunteers
Schizophrenia Research
AUTHOR(S)
Mar 2018
Efficacy and safety of aripiprazole lauroxil once-monthly versus aripiprazole once-monthly long-acting injectable formulations in patients with acute symptoms of schizophrenia: an indirect comparison of two double-blind placebo-controlled studies
Current Medical Research and Opinion
AUTHOR(S)
Mar 2018
Antagonists in the medical management of opioid use disorders: historical and existing treatment strategies
The American Journal on Addictions
AUTHOR(S)
Dec 2017
Efficacy and safety of aripiprazole lauroxil in schizophrenic patients presenting with severe psychotic symptoms during an acute exacerbation
Schizophrenia Research
AUTHOR(S)
Aug 2017
Durability of Therapeutic Response With Long-Term Aripiprazole Lauroxil Treatment Following Successful Resolution of an Acute Episode of Schizophrenia
The Journal of Clinical Psychiatry
AUTHOR(S)
Jul 2017
Metabolic and Endocrine Profiles During 1-Year Treatment of Outpatients with Schizophrenia with Aripiprazole Lauroxil
Psychopharmacology Bulletin
AUTHOR(S)
Jul 2017
A Phase-1 Study Comparing Pharmacokinetic and Safety Profiles of Three Different Dose Intervals of Aripiprazole Lauroxil
Psychopharmacology Bulletin
AUTHOR(S)
Jun 2017
Aripiprazole Lauroxil Compared with Paliperidone Palmitate in Patients with Schizophrenia: An Indirect Treatment Comparison
Value in Health
AUTHOR(S)
